Lipella Pharmaceuticals Inc. (LIPO)
PNK · Healthcare · Biotechnology
Closing price as of 2026-09-10 · Source: TEK2day Finance
Key Metrics
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Quarterly Financials
| Metric | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 174K | 0.00 | 0.00 | 0.00 |
| Gross Profit | (889K) | (993K) | (792K) | (721K) |
| Operating Income | (1.8M) | (1.3M) | (1.4M) | (1.3M) |
| Net Income | (1.4M) | (1.3M) | (1.3M) | (1.3M) |
| Diluted EPS | N/A | $-0.64 | $-0.31 | $-0.28 |
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 259K | 184K | 450K | 536K |
| Gross Profit | (1.2M) | (2.4M) | (2.6M) | (3.1M) |
| Operating Income | (1.9M) | (2.6M) | (4.7M) | (5.1M) |
| Net Income | (1.9M) | (2.6M) | (4.6M) | (5.0M) |
| Diluted EPS | $-2.60 | $-5.12 | $-6.16 | $-4.79 |